Evidence map›Paper›PMID 25484928›Full record

ArticleAlzheimer's research & therapy2014

Association between cell-bound blood amyloid-β(1-40) levels and hippocampus volume.

Oscar Sotolongo-Grau, Pedro Pesini, Sergi Valero, Asunción Lafuente, Mar Buendía, Virginia Pérez-Grijalba, Itziar San José, Marta Ibarria, Miguel A Tejero, Joan Giménez and 5 more

Open access · goldAbstract read
In one paragraph

Article in Alzheimer's research & therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Oscar Sotolongo-GrauAlzheimer Research Center and Memory Clinic, Fundació ACE Memory Clinic, Institut Català de Neurociències Aplicades, Marquès de Sentmenat, 57, Barcelona, 08029, Spain.
Pedro PesiniAraclon Biotech Ltd, Via Hispanidad 21, Zaragoza, 50009, Spain.
Sergi ValeroAlzheimer Research Center and Memory Clinic, Fundació ACE Memory Clinic, Institut Català de Neurociències Aplicades, Marquès de Sentmenat, 57, Barcelona, 08029, Spain ; Department of Psychiatry, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Passeig Vall d'Hebron, 119-129, Barcelona, 08035, Spain.
Asunción LafuenteAlzheimer Research Center and Memory Clinic, Fundació ACE Memory Clinic, Institut Català de Neurociències Aplicades, Marquès de Sentmenat, 57, Barcelona, 08029, Spain.
Mar BuendíaAlzheimer Research Center and Memory Clinic, Fundació ACE Memory Clinic, Institut Català de Neurociències Aplicades, Marquès de Sentmenat, 57, Barcelona, 08029, Spain.
Virginia Pérez-GrijalbaAraclon Biotech Ltd, Via Hispanidad 21, Zaragoza, 50009, Spain.
Itziar San JoséAraclon Biotech Ltd, Via Hispanidad 21, Zaragoza, 50009, Spain.
Marta IbarriaAlzheimer Research Center and Memory Clinic, Fundació ACE Memory Clinic, Institut Català de Neurociències Aplicades, Marquès de Sentmenat, 57, Barcelona, 08029, Spain.
Miguel A TejeroDepartment of Diagnostic Imaging, Clínica Corachan, Buïgas, 19, Barcelona, 08017, Spain.
Joan GiménezDepartment of Diagnostic Imaging, Clínica Corachan, Buïgas, 19, Barcelona, 08017, Spain.
Isabel HernándezAlzheimer Research Center and Memory Clinic, Fundació ACE Memory Clinic, Institut Català de Neurociències Aplicades, Marquès de Sentmenat, 57, Barcelona, 08029, Spain.
Lluís TárragaAlzheimer Research Center and Memory Clinic, Fundació ACE Memory Clinic, Institut Català de Neurociències Aplicades, Marquès de Sentmenat, 57, Barcelona, 08029, Spain.
Agustín RuizAlzheimer Research Center and Memory Clinic, Fundació ACE Memory Clinic, Institut Català de Neurociències Aplicades, Marquès de Sentmenat, 57, Barcelona, 08029, Spain.
Mercé BoadaAlzheimer Research Center and Memory Clinic, Fundació ACE Memory Clinic, Institut Català de Neurociències Aplicades, Marquès de Sentmenat, 57, Barcelona, 08029, Spain.
Manuel SarasaAraclon Biotech Ltd, Via Hispanidad 21, Zaragoza, 50009, Spain.
SOM Biotech (Spain) · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe identification of early, preferably presymptomatic, biomarkers and true etiologic factors for Alzheimer's disease (AD) is the first step toward establishing effective primary and secondary prevention programs. Consequently, the search for a relatively inexpensive and harmless biomarker for AD continues. Despite intensive research worldwide, to date there is no definitive plasma or blood biomarker indicating high or low risk of conversion to AD.

methodsMagnetic resonance imaging and β-amyloid (Aβ) levels in three blood compartments (diluted in plasma, undiluted in plasma and cell-bound) were measured in 96 subjects (33 with mild cognitive impairment, 14 with AD and 49 healthy controls). Pearson correlations were completed between 113 regions of interest (ROIs) (45 subcortical and 68 cortical) and Aβ levels. Pearson correlation analyses adjusted for the covariates age, sex, apolipoprotein E (ApoE), education and creatinine levels showed neuroimaging ROIs were associated with Aβ levels. Two statistical methods were applied to study the major relationships identified: (1) Pearson correlation with phenotype added as a covariate and (2) a meta-analysis stratified by phenotype. Neuroimaging data and plasma Aβ measurements were taken from 630 Alzheimer's Disease Neuroimaging Initiative (ADNI) subjects to be compared with our results.

resultsThe left hippocampus was the brain region most correlated with Aβ(1-40) bound to blood cell pellets (partial correlation (pcor) = -0.37, P = 0.0007) after adjustment for the covariates age, gender and education, ApoE and creatinine levels. The correlation remained almost the same (pcor = -0.35, P = 0.002) if phenotype is also added as a covariate. The association between both measurements was independent of cognitive status. The left hemisphere entorhinal cortex also correlated with Aβ(1-40) cell-bound fraction. AB128 and ADNI plasma Aβ measurements were not related to any brain morphometric measurement.

conclusionsAssociation of cell-bound Aβ(1-40) in blood with left hippocampal volume was much stronger than previously observed in Aβ plasma fractions. If confirmed, this observation will require careful interpretation and must be taken into account for blood amyloid-based biomarker development.

Identifiers

PMID25484928
PMCPMC4255526
OpenAlexW2114606300

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.